• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » New Augmentation Strategies in OCD

New Augmentation Strategies in OCD

July 3, 2019
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Naderi S, Psychiatry Clin Neurosci 2019;73(4):169–174 and Zheng H et al, Eur Neuropsychopharmacol 2019;29(3):397–404


Study types: Positive RCTs


Serotonergic agents—both SSRIs and clomipramine—have historically been the cornerstone of pharmacotherapy for OCD. However, response rates are notoriously low, and few patients achieve full remission. Atypical antipsychotics have so far failed to distinguish themselves as viable augmentation agents. Two novel augmentation strategies—amantadine and methylphenidate—recently underwent placebo-controlled trials in OCD, and we’ll review those results here.


Amantadine
Amantadine is a glutamatergic and dopaminergic agent that was ­originally approved in 1966 for the ­influenza virus and, more recently, in an ­extended-release form for Parkinson’s disease. Several other glutamatergic agents have demonstrated benefits for OCD in small (sample sizes of 15–50), double-blind, placebo-controlled augmentation trials: memantine, riluzole, N-acetylcysteine, and ketamine. Amantadine has also been found to enhance energy and cognition in Alzheimer’s dementia, multiple sclerosis, depression, and ADHD; and reduce irritability in autism and traumatic brain injury.


The most recent amantadine study randomized 100 subjects with moderate to severe OCD in a double-blind manner to receive fluvoxamine (Luvox; titrated up to 200 mg/day by week 4) plus either amantadine 100 mg/day or placebo over 12 weeks. Improvement was assessed at weeks, 4, 10, and 12 using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Y-BOCS scores were significantly lower in the subjects receiving amantadine augmentation compared to those receiving placebo augmentation at week 4 (reduction of 8.4 vs 5.6; p < 0.01) and at the 12-week endpoint (reduction of 12.4 vs 9.7; p < 0.05), though the difference fell just short of significance at week 10 (reduction of 11.9 vs 9.4; p = 0.08). The number needed to treat to see response was 2.5. As has historically been the case, amantadine was very well tolerated, with no side effects that were reported at a statistically significant higher rate than placebo.


Methylphenidate
Stimulants have been used to augment SSRIs in OCD since the early 1980s, but they can also induce compulsive behaviors. As the first placebo-controlled trial of a stimulant in OCD, this new study brings needed clarity.


The methylphenidate trial enrolled 44 patients with significant OCD who failed to respond to an effective dose of fluvoxamine. They were randomized for 8 weeks to 250 mg fluvoxamine and placebo, or 250 mg of fluvoxamine and extended-release methylphenidate. Subjects in the treatment arm blindly received 18 mg of methylphenidate for the first 4 weeks and 36 mg for the remainder of the study. The primary outcome was the total score on the Y-BOCS.


Patients given methylphenidate in combination with fluvoxamine showed robust improvement compared to those who received fluvoxamine alone. The treatment group had a significant reduction in their total OCD symptoms as measured by the Y-BOCS (reduction of 6.7 vs 1.9). Additionally, the treatment group showed a reduction in the obsessive subscale of the Y-BOCS (reduction of 5.5 vs -0.2). The number needed to treat to see response was 1.8. Secondary measures of depression and anxiety also showed significant improvement. Side effects were minimal (palpitations and headache). Dropout rates were similar in the treatment and placebo arms, and no subjects dropped out due to adverse effects.


Notably, the two studies differed in the types of patients enrolled. In the stimulant study, the patients had failed a trial of fluvoxamine; in the amantadine study, the patients began fluvoxamine along with amantadine.


TCPR’S TAKE
These studies were well designed and build on previous findings as well as plausible biological pathways in OCD. The number needed to treat translates to an impressive 50% response rate, but with the small sample sizes, that estimate is very rough. Amantadine and methylphenidate have been used for a long time, so we have a good sense of their risks. Both are reasonable options when OCD persists after standard ­treatments.



For more on this subject, listen to our podcast, “How to Use Amantadine” 


General Psychiatry
KEYWORDS amphetamines novel-medications ocd pharmacology
Michael Posternak, MD.

Adjuvant Clonidine for Mania

More from this author
www.thecarlatreport.com
Issue Date: July 3, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Side Effects Part I, TCPR, June/July 2019
Mood Stabilizers and Stroke Risk in Bipolar Disorder
Lithium in Geriatric Depression
New Augmentation Strategies in OCD
Esketamine Gets FDA Approval
Risk Evaluation and Mitigation Strategy (REMS) Programs
Medication Side Effects: Nausea, Sweating, and Dry Mouth
Are Auditory Hallucinations Ever Normal?
Brexanolone (Zulresso) for Postpartum Depression
A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness
A New Proposal for SSRI Withdrawal
SSRI withdrawal symptoms
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.